Amgen was listed 35th in the 2004 ranking of the 500 largest North American companies who have performed best for investors.
Business 2.0
Amgen ranked 58th in the annual list of the 100 fastest-growing technology companies in 2004.
Financial Times
Amgen ranked 29th in Europe’s Financial Times "Global 500" in 2003.
Forbes
Amgen was named Forbes’ "Company of the Year" for 2004.
Fortune
On Fortune Magazine’s 2004 list of "America’s Most Admired Companies," Amgen ranked fifth in the pharmaceutical industry.
Amgen ranked 246th on the Fortune 500 list and 27th among California companies in 2004.
Amgen was named by Fortune in 2005, for the sixth time, as one of the "100 Best Companies to Work for in America."
IndustryWeek
Kevin Sharer was named IndustryWeek’s 2004 "CEO of the Year."
Med Ad News
Amgen has been named among the top two most admired biotech companies for four consecutive years (2001—2004).
Pharmaceutical Executive
Amgen tied for first place in Pharmaceutical Executive's 2005 Industry Audit, which analyzed the financial performance of 16 publicly traded pharmaceutical and biotechnology companies, and assessed overall company performance.
Amgen was one of three companies receiving the highest quality rating in a 2003 ranking of pharmaceutical companies by ethics reputation.
Science
Amgen ranked second in Science magazine’s 2005 survey of top employers in the biotechnology and pharmaceutical industries.
The Scientist
As reported in a March 2004 article, a study by Thomson ISI ranked Amgen seventh among the world’s leading research institutions in molecular biology and genetics, based on the number of citations per research papers produced.
Amgen was named by The Scientist in June 2004 as one of the "Best Places to Work in Industry," ranking fifth among the top 10 large companies.
